Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
{{output}}
The treatment landscape of metastatic urothelial cancer (mUC) remained unchanged for over 30 years until the approval of immune checkpoint inhibitors (ICIs) in 2016. Since then, several ICIs have been approved for the treatment of mUC. In addition, recent mole... ...
